A Phase II Study of Obinutuzumab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Mar 2018
At a glance
- Drugs Lenalidomide (Primary) ; Obinutuzumab (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 21 Mar 2018 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 17 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 06 Dec 2016 Status changed from not yet recruiting to recruiting.